441356-84-9

Upstream product

• 107-30-2 chloromethyl methyl ether 
• 59398-98-0 (2-phenyl-1,3-oxazol-4-yl)methanol 

Downstream Products

• 694503-62-3 methyl (E)-4-(4-{[5-(tert-butyldiphenylsilyloxymethyl)-2-phenyl-1,3-oxazol-4-yl]methoxy}benzyloxyimino)-4-phenylbutanoate 
• 675147-97-4 5-(tert-butyldiphenylsilyloxymethyl)-4-(methoxymethoxymethyl)-2-phenyl-1,3-oxazole 
• 675148-95-5 [5-(tert-butyldiphenylsilyloxymethyl)-2-phenyl-1,3-oxazol-4-yl]methanol 
• 675147-96-3 (4-methoxymethoxymethyl-2-phenyl-oxazol-5-yl)-methanol 
• 441356-85-0 4-methoxymethoxymethyl-2-phenyl-5-oxazolecarbaldehyde 

Relevant academic research and scientific papers

Studies on non-thiazolidinedione antidiabetic agents. 3. Preparation and biological activity of the metabolites of TAK-559

Preparation and biological activity of the metabolites of the potent antihyperglycemic and antihyperlipidemic agent, (E)-4-{4-[(5-methyl-2-phenyl-1, 3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyric acid (TAK-559) (1), were investigated. Metabolites M

ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF

An alkanoic acid derivative useful as a prophylactic or therapeutic agent of diabetes mellitus, hyperlipidemia, impaired glucose tolerance and the like can be provided by a compound represented by the formula wherein R1 is an optionally substituted 5-membered aromatic heterocyclic group; X is a bond and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond and the like; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is -(CH2)n-Z1- (n is an integer of 1 to 8 and Z1 is an oxygen atom and the like) and the like; ring B is a pyridine ring optionally further having 1 to 3 substituents, and the like; U is a bond and the like; W is a divalent hydrocarbon group having 1 to 20 carbon atoms; and R3 is -OH and the like, provided that, when ring B is a benzene ring optionally further having 1 to 3 substituents, U should be a bond, or a salt thereof.